Michael Schmitt
Ruprecht-Karls-Universität Heidelberg
H-index: 72
Europe-Germany
Top articles of Michael Schmitt
Third-generation CD19. CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis
Annals of the Rheumatic Diseases
2024/4/1
Michael Schmitt
H-Index: 35
CD70-specific CAR-T cell therapy for the treatment of glioblastoma
Cancer Research
2024/3/22
Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study
eClinicalMedicine
2024/3/1
Michael Schmitt
H-Index: 35
Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T cell therapy
Blood Advances
2024/2/17
Lei Wang
H-Index: 4
Min Lin
H-Index: 2
Hao Yao
H-Index: 0
Qian Chen
H-Index: 26
Zhiqiang Guo
H-Index: 12
Michael Schmitt
H-Index: 35
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre …
The Lancet Haematology
2024/2/1
Domenico Russo
H-Index: 10
Michael Schmitt
H-Index: 35
In vitro functionality and endurance of GMP-compliant point-of-care BCMA. CAR-T cells at different timepoints of cryopreservation
International Journal of Molecular Sciences
2024/1/23
Lei Wang
H-Index: 4
Michael Schmitt
H-Index: 35
The remission status of AML patients post alloSCT is associated with a distinct single-cell bone marrow T cell signature
Blood
2024/1/11
Yi Liu
H-Index: 21
Michael Schmitt
H-Index: 35
Species comparison: human and minipig PBMC reactivity under the influence of immunomodulating compounds in vitro
Frontiers in Immunology
2024/1/9
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity
Journal for Immunotherapy of Cancer
2024
Michael Schmitt
H-Index: 35
Claudia Lengerke
H-Index: 27
Proteomic profiling identifies Serpin B9 as mediator of resistance to CAR T-cell and bispecific antibody treatment in B-cell lymphoma
bioRxiv
2023
439 Cardiovascular safety of chimeric antigen receptor (CAR) T cell therapy
2023/11/1
Michael Schmitt
H-Index: 35
First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
Biomarker Research
2023/10/14
Michael Schmitt
H-Index: 35
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
Nature Cancer
2023/1
Maike Janssen
H-Index: 1
Lars Bullinger
H-Index: 62
Barbara Müller
H-Index: 8
Ralf Bartenschlager
H-Index: 69
Michael Schmitt
H-Index: 35
Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation
Transplantation and Cellular Therapy
2023/10/1
Michael Schmitt
H-Index: 35
Induction of long-lasting regulatory B lymphocytes by modified immune cells in kidney transplant recipients
Journal of the American Society of Nephrology
2023/1/1
P-011 Hematopoietic reconstitution and infections after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma are associated with pre-CAR-T bridging therapies
Clinical Lymphoma Myeloma and Leukemia
2023/9/1
Christian Michel
H-Index: 6
Michael Schmitt
H-Index: 35
PB1790: LOOKING ‘BENEATH’THE SURFACE: PROTEOMICS AND GLYCIPROTEOMICS REVEAL NOVEL TARGETS FOR CAR-T CELL THERAPIES IN ACUTE MYELOID LEUKEMIA (AML)
HemaSphere
2023/8/1
Symptomatic Patients with Hyperleukocytic FLT3-ITD Mutated Acute Myeloid Leukemia Might Benefit from Leukapheresis
Cancers
2023/12/21
Michael Schmitt
H-Index: 35
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Journal of Hematology & Oncology
2023/7/22
The Ig Superfamily Ligand B7H6 Subjects Activated T Cells to NK Cell Surveillance and Limits CAR T Cell Persistence
Blood
2023/11/28
